AUS
NZ
UK
CA
USA
IND
Highlights:
Rhythm Pharmaceuticals reported strong revenue growth in Q3 2024, with total revenues of $33.3 million, marking a 14% quarter-over-quarter increase.
The company continues to make progress with its clinical programs, particularly for hypothalamic obesity, with phase 3 trials on track for a 2025 data readout.
Operating expense guidance for 2024 has been reduced, reflecting improved financial management.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) has delivered notable revenue growth in the third quarter of 2024, achieving $33.3 million, which represents a 14% increase from the previous quarter. The company’s domestic revenue accounted for a significant portion of this total, reaching $23.3 million, while international sales grew substantially by 35% from the previous quarter to $10 million. This strong growth demonstrates the expanding reach of Rhythm’s product portfolio in both established and emerging markets.
Despite the positive revenue performance, the company continues to invest heavily in its research and development, with Q3 R&D expenses rising to $37.9 million. The company remains focused on advancing its clinical programs, particularly the phase 3 trial for hypothalamic obesity, which is slated for a data readout in the first half of 2025. Early-stage real-world data from France for hypothalamic obesity patients have shown promising results, with patients experiencing a significant reduction in body mass index (BMI), further bolstering confidence in the program.
However, Rhythm is facing some operational challenges. The cost of sales saw a slight increase due to higher labor and overhead costs, and the company also acknowledged some issues with clinical trial enrollment, particularly in certain substudies. Additionally, while the company has strong commercial coverage from Medicaid and commercial insurance, Medicare remains a challenge, with a significant portion of prescriptions transitioning to free drug due to lack of coverage.
In terms of financial management, Rhythm has reduced its operating expense guidance for 2024, from $250-$270 million to $245-$255 million, signaling better control over expenditures and improved operating leverage. This reflects the company's commitment to optimizing its financial position while continuing to scale its clinical and commercial operations globally.
